EydisBio, Inc.

EydisBio, Inc. is a Durham, NC-based biotechnology startup focused on developing highly selective and potent small molecule kinase inhibitors. Their primary focus is on targeting TAK1, a protein kinase involved in various inflammatory pathways, to create safer and more effective treatments for autoimmune and inflammatory diseases. The company's unique drug discovery platform, the Universal Purinome Capture Platform (UPCP), allows them to identify and develop novel kinase inhibitors with high selectivity for specific disease targets.

EydisBio's commitment to innovation is evident in its development of the first highly selective, orally bioavailable TAK1 inhibitor, a novel class of drugs with potential applications in the treatment of rheumatoid arthritis, chronic pain, systemic sclerosis, and other inflammatory conditions. The company boasts a team of experienced scientists, business advisors, and financial consultants dedicated to creating solutions for unmet medical needs in the field of autoimmune and inflammatory diseases.

EydisBio is a small biotech startup dedicated to developing novel small molecule therapies for patients suffering from autoimmune and inflammatory diseases. Their mission is to leverage their unique platform technology and expertise to discover and develop highly selective kinase inhibitors that address serious unmet medical needs in these areas, ultimately improving the lives of patients.

EydisBio fosters a collaborative and innovative culture, attracting top talent in the fields of pharmacology, chemistry, and biology. The company prioritizes scientific excellence and the development of novel small molecule therapies to address unmet medical needs. Its team members are passionate about their work and driven by a shared goal of creating solutions for patients suffering from autoimmune and inflammatory diseases.